Pulmonary Fibrosis Treatment Market To Enter The “Decisive Mode” Between 2029

Posted by Merin John on April 22nd, 2021

Globally, increasing diagnosis rate for the pulmonary fibrosis is expected to drive the growth of the pulmonary fibrosis treatment market. According to the latest research by the company, the global pulmonary fibrosis treatment market is projected to account for a market value of ~US$ 4.4 Bn by the end of 2029. The report also projects significant growth potential for the pulmonary fibrosis treatment market throughout the forecast period.

Increasing diagnosis rate of the pulmonary fibrosis due to enhanced understanding of the disease is the prime driver of the pulmonary fibrosis treatment market. Although the disease understanding and understanding of the associated symptoms has advanced immensely, misdiagnosis still remains as high as 40% in developed regions, potentially hampering the growth of the pulmonary fibrosis treatment market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/30070

Company Profiles:

Genentech, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Dr. Reddy’s Laboratories Ltd.

Alkem Laboratories Ltd.

Alniche Life Sciences Pvt Ltd

MHS Pharmaceuticals

Torrent Pharmaceuticals Ltd

Anthem Biopharma Pvt Ltd

Panacea Biotec

Zydus Healthcare Ltd

Nuper Therapeutics

Fresenius Kabi India Pvt Ltd.

Sun Pharmaceutical Industries Ltd

Increasing literature about the pulmonary fibrosis treatment, causes and increasing small and medium sized regional studies by universities, pulmonary fibrosis organizations are assisting to improve the overall awareness about the disease in the general population.

The similarities of symptoms of pulmonary fibrosis with other respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, etc. are the major impediments in the precise diagnosis of the disease delaying the pulmonary fibrosis treatment.